GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Operating Income

PACB (Pacific Biosciences of California) Operating Income : $-313.4 Mil (TTM As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California Operating Income?

Pacific Biosciences of California's Operating Income for the three months ended in Sep. 2024 was $-62.9 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-313.4 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pacific Biosciences of California's Operating Income for the three months ended in Sep. 2024 was $-62.9 Mil. Pacific Biosciences of California's Revenue for the three months ended in Sep. 2024 was $40.0 Mil. Therefore, Pacific Biosciences of California's Operating Margin % for the quarter that ended in Sep. 2024 was -157.40%.

Warning Sign:

Pacific Biosciences of California Inc operating margin has been in a 5-year decline. The average rate of decline per year is -9.8%.

Pacific Biosciences of California's 5-Year average Growth Rate for Operating Margin % was -9.80% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pacific Biosciences of California's annualized ROC % for the quarter that ended in Sep. 2024 was -26.38%. Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -205.34%.


Pacific Biosciences of California Operating Income Historical Data

The historical data trend for Pacific Biosciences of California's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Operating Income Chart

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100.55 -104.39 -178.16 -304.82 -310.37

Pacific Biosciences of California Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.78 -86.39 -81.43 -82.65 -62.91

Pacific Biosciences of California Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-313.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Biosciences of California  (NAS:PACB) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pacific Biosciences of California's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-251.628 * ( 1 - 0% )/( (959.745 + 947.658)/ 2 )
=-251.628/953.7015
=-26.38 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1509.491 - 39.944 - ( 509.802 - max(0, 78.39 - 628.139+509.802))
=959.745

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1450.052 - 31.247 - ( 471.147 - max(0, 59.997 - 584.234+471.147))
=947.658

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-228.748/( ( (57.301 + max(52.434, 0)) + (49.296 + max(63.765, 0)) )/ 2 )
=-228.748/( ( 109.735 + 113.061 )/ 2 )
=-228.748/111.398
=-205.34 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.433 + 68.594 + 17.31) - (39.944 + 19.212 + 6.747)
=52.434

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29.383 + 65.737 + 17.967) - (31.247 + 17.292 + 0.783)
=63.765

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Pacific Biosciences of California's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-62.907/39.967
=-157.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pacific Biosciences of California Operating Income Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Executives
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Jeff Eidel officer: See Remarks 1305 O'BRIEN DR., MENLO PARK CA 94025
Oene Mark Van officer: Chief Operating Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michele Farmer officer: Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
David W Meline director 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim officer: Chief Financial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson director 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen officer: Chief Commercial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller director 400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer officer: VP Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez director 3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston director
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein director 1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025